🔴 LIVE: The Secrets of ProPicks AI Success Revealed + November’s List FREEWatch Now

After-Hours Movers: Imara Gains on Merger, Travere Therapeutics Falls on PDUFA Delay

Published 10/13/2022, 05:24 PM
Updated 10/13/2022, 05:29 PM
© Reuters.  After-Hours Movers: Imara Gains on Merger, Travere Therapeutics Falls on PDUFA Delay
TVTX
-
RETA
-
ELVN
-
EAR
-
AMPX
-

After-Hours Stock Movers:

Imara Inc (NASDAQ:IMRA19% HIGHER; Enliven Therapeutics, Inc., a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, and Imara Inc. announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction.

Travere Therapeutics Inc (NASDAQ:TVTX5% LOWER; announced that following late-cycle review interactions with the U.S. Food and Drug Administration (FDA), the Company expects the previously assigned Prescription Drug User Fee Act (PDUFA) target action date of November 17, 2022 for its New Drug Application (NDA) under Subpart H for accelerated approval of sparsentan for the treatment of IgA nephropathy to be extended by three months.

Eargo Inc (NASDAQ:EAR) 3% LOWER; announced that the record date for its proposed rights offering is October 24, 2022 at 5:00 p.m. Eastern Time (the Record Date).

Amprius Technologies Inc (NYSE:AMPX2% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $14.00.

Reata Pharmaceuticals, Inc. (Nasdaq: NASDAQ:RETA) 1% HIGHER; announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that it does not plan to hold an advisory committee meeting in connection with its review of the Company’s New Drug Application (“NDA”) for omaveloxolone for the treatment of patients with Friedreich’s ataxia.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.